Get the Stockscreener App
60.43
0.22%
-0.1369
Globus Medical Inc stock is traded at $60.43, with a volume of 371.98K.
It is down -0.22% in the last 24 hours and up +7.27% over the past month.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
See More
Previous Close:
$60.57
Open:
$60.57
24h Volume:
371.98K
Relative Volume:
0.25
Market Cap:
$8.16B
Revenue:
$2.51B
Net Income/Loss:
$185.56M
P/E Ratio:
45.10
EPS:
1.34
Net Cash Flow:
$517.59M
1W Performance:
+1.69%
1M Performance:
+7.27%
6M Performance:
-28.76%
1Y Performance:
-13.49%
1-Day Range:
$60.29
$60.94
1-Week Range:
$59.43
$63.11
52-Week Range:
$51.79
$94.93
Globus Medical Inc Stock (GMED) Company Profile
Name
Globus Medical Inc
Sector
Industry
Phone
610-930-1800
Address
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA
Compare GMED with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GMED
Globus Medical Inc
|
60.43 | 8.18B | 2.51B | 185.56M | 517.59M | 1.34 |
|
ABT
Abbott Laboratories
|
131.26 | 229.31B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.98 | 152.87B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
381.75 | 146.01B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.84 | 119.18B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.30 | 45.95B | 5.69B | 1.41B | 577.90M | 6.95 |
Globus Medical Inc Stock (GMED) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-10-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-20-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-18-24 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-20-23 | Initiated | ROTH MKM | Buy |
| Sep-19-23 | Upgrade | Stifel | Hold → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-13-23 | Downgrade | BofA Securities | Buy → Underperform |
| Feb-10-23 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-10-23 | Downgrade | Loop Capital | Buy → Hold |
| Feb-10-23 | Downgrade | Needham | Buy → Hold |
| Feb-10-23 | Downgrade | Truist | Buy → Hold |
| Feb-10-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-28-22 | Initiated | Wells Fargo | Overweight |
| Jan-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-13-21 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-29-21 | Initiated | Loop Capital | Buy |
| Feb-18-21 | Resumed | Needham | Buy |
| Dec-08-20 | Initiated | Citigroup | Buy |
| Oct-20-20 | Initiated | Stifel | Hold |
| Aug-06-20 | Reiterated | Needham | Buy |
| Aug-06-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-21-20 | Initiated | Northland Capital | Market Perform |
| Jul-06-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-08-20 | Reiterated | Needham | Buy |
| Mar-18-20 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Dec-12-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Aug-02-19 | Reiterated | Needham | Buy |
| May-24-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| May-03-19 | Reiterated | Needham | Buy |
| Feb-28-19 | Upgrade | UBS | Neutral → Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-02-18 | Reiterated | Needham | Buy |
| Jun-27-18 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| May-03-18 | Reiterated | Needham | Buy |
| Apr-04-18 | Upgrade | Needham | Hold → Buy |
View All
Globus Medical Inc Stock (GMED) Latest News
Globus Medical Inc. Outperforms Peers on Volume MetricsTrade Analysis Summary & Precise Swing Trade Alerts - sundaytimes.kr
Is Globus Medical Inc. a defensive stockJuly 2025 Outlook & Proven Capital Preservation Tips - sundaytimes.kr
Globus Medical Inc. Building a Base Near SupportWeekly Trade Report & Weekly Momentum Stock Picks - newsyoung.net
Is Globus Medical Inc. a turnaround storyChart Signals & Risk Controlled Stock Pick Alerts - sundaytimes.kr
Globus Medical (GMED): A High-Quality Growth Story with Strong Earnings and Strategic Momentum - AInvest
Globus Medical's (NYSE:GMED) Strong Earnings Are Of Good Quality - Yahoo Finance
Globus Medical to Announce Q2 2025 Financial Results on August 7, Followed by Investor Call - MSN
Globus Medical Inc. Ranks High in Smart Money TrackerJuly 2025 Earnings & Intraday High Probability Alerts - newsyoung.net
Globus Medical Sees Robust Growth Amidst Challenges: Key Takeaways from Q2 Earnings Call. - AInvest
Orthobiologics Market to Experience Massive Growth by 2032 - openPR.com
Globus Medical’s Q2 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
2 Healthcare Stocks to Consider Right Now and 1 We Find Risky - FinancialContent
Globus Medical Stock Up on Q2 Earnings & Revenue Beat, Margins Expand - Nasdaq
UFP Technologies, Inspire Medical Systems, Globus Medical, Neogen, and Dentsply Sirona stocks soar on positive inflation data, Fed rate cut hopes. - AInvest
Inspire Medical Systems, UFP Technologies, Globus Medical, Neogen, and Dentsply Sirona Shares Skyrocket, What You Need To Know - TradingView
Globus Medical (GMED) Receives Hold Rating from Truist Financial and Needham, Upgrade to Buy from TR | OpenAI – 4o - AInvest
Globus Medical, Inc. (NYSE:GMED) Q2 2025 Earnings Call Transcript - Insider Monkey
Globus Medical (GMED) Receives a Hold from Truist Financial - The Globe and Mail
Quant Strategy Flags Globus Medical Inc. for EntryWeekly Chart Analysis With Entry Advice Provided - beatles.ru
Globus Medical, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - 富途牛牛
Globus Medical Delivers Strong Q2 Results, Reaffirms 2025 Outlook - MSN
A Quick Look at Today's Ratings for Globus Medical(GMED.US), With a Forecast Between $66 to $106 - 富途牛牛
Are Investors Undervaluing Globus Medical, Inc. (NYSE:GMED) By 43%? - Yahoo Finance
RBC Capital Sticks to Its Buy Rating for Globus Medical (GMED) - The Globe and Mail
Globus Medical's Q2 2025 Earnings and Strategic Leadership Shifts: A Blueprint for Sustained Growth - AInvest
Globus Medical Surges 8.47% on $210M Volume as Q2 Sales Hit $745M Propelling It into Top 500 High-Volume Stocks - AInvest
Globus Medical: A Strategic Powerhouse in the Evolving Spine Care Landscape - AInvest
Globus Medical reaffirms $2.8B–$2.9B 2025 sales outlook as integration advances and U.S. Spine momentum builds - MSN
Globus Medical Reiterates $2.8B-$2.9B 2025 Sales Outlook Amid Integration Progress and Growing US Spine Market - AInvest
Globus Medical (GMED) Stock Rises on Better-Than-Expected Q2 ResultsNews and Statistics - IndexBox
How Globus Medical's (GMED) Surge in Net Income and Sales May Reshape Its 2025 Outlook - simplywall.st
Barclays raises Globus Medical stock price target to $106 on margin strength - Investing.com Canada
Globus Medical 2025 Q2 Earnings Record Net Income Surges 538.7% - AInvest
Globus Medical (GMED) Shares Skyrocket, What You Need To Know - TradingView
Transcript : Globus Medical, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Globus Medical worldwide sales up 18.4% to USD 745.3M in Q2 2025 - Medical Buyer
Globus Medical (NYSE:GMED) Exceeds Q2 Expectations - TradingView
Globus Medical shares rise 6.90% premarket after Q2 sales, adjusted EPS beat expectations. - AInvest
Globus Medical Inc (GMED) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Globus Medical: Q2 Earnings Snapshot - Greenwich Time
Globus Medical Reports Strong Q2 2025 Growth - TipRanks
Globus Medical Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Decoding Globus Medical Inc (GMED): A Strategic SWOT Insight - GuruFocus
Globus Medical Q2 Earnings Top Consensus, Revenue Hits $745.3M - AInvest
Globus Medical Outperforms Expectations With Strong Q2 Results - Finimize
Globus Medical's Q2 2025 Earnings Outperformance: A Masterclass in Operational Execution and Strategic Innovation - AInvest
Globus Medical (GMED) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Globus Medical earnings beat by $0.10, revenue topped estimates - Investing.com Canada
Globus Medical (GMED) Q2 Revenue Up 18% - AOL.com
Globus Medical (GMED) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Globus Medical Q2 sales, adjusted EPS beat expectations - MarketScreener
Globus Medical Inc Stock (GMED) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.07%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):